II期临床-话题@MedSci

#II期临床#

478篇内容 | 2595人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524767, encodeId=6cbe1524e6740, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, objectType=article, longId=185521, objectId=11cc18552145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11cc18552145, replyNumber=0, likeNumber=58, createdTime=2020-01-02, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11cc18552145, moduleTitle=HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11cc18552145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524766, encodeId=79dd1524e6610, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=10, createdTime=2020-01-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524765, encodeId=07071524e656c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, objectType=article, longId=185186, objectId=397c185186ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397c185186ea, replyNumber=0, likeNumber=11, createdTime=2019-12-26, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397c185186ea, moduleTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397c185186ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524764, encodeId=09631524e641e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=104, createdTime=2019-12-22, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524763, encodeId=ee091524e6332, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, objectType=article, longId=184902, objectId=8f0518490243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f0518490243, replyNumber=0, likeNumber=87, createdTime=2019-12-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f0518490243, moduleTitle=诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f0518490243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524762, encodeId=b6c61524e62ce, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%, objectType=article, longId=184847, objectId=ab3518484e02, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab3518484e02, replyNumber=0, likeNumber=68, createdTime=2019-12-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab3518484e02, moduleTitle=阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab3518484e02)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524761, encodeId=f9da1524e6131, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, objectType=article, longId=184569, objectId=5a93184569d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a93184569d3, replyNumber=0, likeNumber=59, createdTime=2019-12-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a93184569d3, moduleTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a93184569d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524760, encodeId=5ea41524e60e9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, objectType=article, longId=184494, objectId=2df618449455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2df618449455, replyNumber=0, likeNumber=56, createdTime=2019-12-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2df618449455, moduleTitle=Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2df618449455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524759, encodeId=aadc1524e59e8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, objectType=article, longId=184287, objectId=1a1218428e0d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a1218428e0d, replyNumber=0, likeNumber=61, createdTime=2019-12-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a1218428e0d, moduleTitle=吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a1218428e0d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524758, encodeId=1ae41524e5854, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=GSK与NIH签署协议，开展新型艾滋病毒药物bNAb的II期临床, objectType=article, longId=183459, objectId=ff15183459d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff15183459d7, replyNumber=0, likeNumber=88, createdTime=2019-11-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff15183459d7, moduleTitle=GSK与NIH签署协议，开展新型艾滋病毒药物bNAb的II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff15183459d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524757, encodeId=27d61524e57de, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景, objectType=article, longId=183284, objectId=b20218328463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b20218328463, replyNumber=0, likeNumber=84, createdTime=2019-11-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b20218328463, moduleTitle=PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b20218328463)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524756, encodeId=afbe1524e56a2, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=12, createdTime=2019-11-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524755, encodeId=9ef61524e5570, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, objectType=article, longId=183160, objectId=386c183160e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=386c183160e6, replyNumber=0, likeNumber=8, createdTime=2019-11-19, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=386c183160e6, moduleTitle=2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=386c183160e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524754, encodeId=93aa1524e5437, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著, objectType=article, longId=182880, objectId=6912182880b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6912182880b4, replyNumber=0, likeNumber=74, createdTime=2019-11-14, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6912182880b4, moduleTitle=Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6912182880b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524753, encodeId=59d01524e531e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, objectType=article, longId=182745, objectId=f0a2182e457c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0a2182e457c, replyNumber=0, likeNumber=64, createdTime=2019-11-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0a2182e457c, moduleTitle=ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0a2182e457c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524752, encodeId=d1ea1524e522c, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=爱科百发抗呼吸道合胞病毒新药Ziresovir对住院婴幼儿患者的国际II期临床概念验证试验取得突破性结果, objectType=article, longId=182517, objectId=1d7618251e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d7618251e0b, replyNumber=0, likeNumber=64, createdTime=2019-11-08, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d7618251e0b, moduleTitle=爱科百发抗呼吸道合胞病毒新药Ziresovir对住院婴幼儿患者的国际II期临床概念验证试验取得突破性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d7618251e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524751, encodeId=21681524e51dd, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, objectType=article, longId=182123, objectId=bacc18212334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacc18212334, replyNumber=0, likeNumber=61, createdTime=2019-10-31, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacc18212334, moduleTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacc18212334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524750, encodeId=b6a61524e5070, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, objectType=article, longId=182069, objectId=fe64182069a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe64182069a8, replyNumber=0, likeNumber=60, createdTime=2019-10-30, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe64182069a8, moduleTitle=维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe64182069a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524749, encodeId=d78b1524e49d4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=12, createdTime=2019-10-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524748, encodeId=a8451524e481f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验, objectType=article, longId=181882, objectId=a91918188212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91918188212, replyNumber=0, likeNumber=82, createdTime=2019-10-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91918188212, moduleTitle=礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91918188212)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

HB-201治疗人乳头瘤病毒16阳性癌症的I/II期临床试验

2020-01-02

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-01-01

柳叶一刀 (审核中...)

前往app查看评论内容

#II期临床#

儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验

2019-12-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2019-12-22

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

诺华在III期临床失败后，放弃其口服哮喘药物fevipiprant

2019-12-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

阿斯利康的ADC药物在治疗晚期乳腺癌的II期临床中，疾病控制率达97.3%

2019-12-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

2019-12-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：奥贝胆酸治疗非酒精性脂肪性肝炎III期临床获得成功

2019-12-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

吉利德的JAK1抑制剂filgotinib治疗类风湿性关节炎III期临床成功

2019-12-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

GSK与NIH签署协议，开展新型艾滋病毒药物bNAb的II期临床

2019-11-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

PureTech的新型口服制剂KarXT在治疗精神分裂症的II期临床中展现前景

2019-11-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-11-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

2019年美国心脏协会科学会议：Rilonacept治疗复发性心包炎的II期临床数据

2019-11-19

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：Resmetirom治疗非酒精性脂肪性肝炎II期临床效果显著

2019-11-14

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ObsEva在令人失望的结果后，放弃了其口服催产素受体拮抗剂nolasiban用于增加体外受精妊娠率的III期临床

2019-11-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

爱科百发抗呼吸道合胞病毒新药Ziresovir对住院婴幼儿患者的国际II期临床概念验证试验取得突破性结果

2019-11-08

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究

2019-10-31

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

维昇药业宣布其TransCon人生长激素，在中国未经修饰的长效人生长激素即将在国内开展III期临床研究

2019-10-30

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2019-10-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

礼来表示没有计划重新审查其阿兹海默氏药物索拉珠单抗已经失败的III期临床实验

2019-10-26

科室
- - 订阅+
  - 更多科室
工具
服务